Quantum-Si Expands Collaboration with SkyWater to Develop New Chip Production Process Critical for Groundbreaking New Proteomics Platform
Quantum-Si (QSI) and SkyWater Technology are expanding their collaboration to develop the consumable for Proteus™, QSI's next-generation protein sequencing platform. This builds upon their existing partnership since 2021 on the first-generation Platinum® platform. SkyWater will continue supplying consumables for Platinum Pro while supporting Proteus commercialization. The new platform aims to enable simultaneous large factor protein sequencing with enhanced accuracy. SkyWater, certified to ISO 13485 Quality Standard for Medical Devices, will leverage its Technology as a Service (TaaS) model and manufacturing capabilities to support this development.
Quantum-Si (QSI) e SkyWater Technology stanno ampliando la loro collaborazione per sviluppare i materiali consumabili per Proteus™, la piattaforma di sequenziamento proteico di nuova generazione di QSI. Questo si basa sulla loro partnership esistente dal 2021 sulla piattaforma di prima generazione Platinum®. SkyWater continuerà a fornire consumabili per Platinum Pro mentre supporta la commercializzazione di Proteus. La nuova piattaforma mira a consentire il sequenziamento simultaneo di proteine di grande fattore con una precisione migliorata. SkyWater, certificata secondo lo standard di qualità ISO 13485 per dispositivi medici, sfrutterà il suo modello di Tecnologia come Servizio (TaaS) e le capacità produttive per supportare questo sviluppo.
Quantum-Si (QSI) y SkyWater Technology están ampliando su colaboración para desarrollar el material consumible para Proteus™, la plataforma de secuenciación de proteínas de nueva generación de QSI. Esto se basa en su asociación existente desde 2021 en la primera generación de la plataforma Platinum®. SkyWater continuará suministrando consumibles para Platinum Pro mientras apoya la comercialización de Proteus. La nueva plataforma tiene como objetivo permitir la secuenciación de proteínas de gran tamaño de manera simultánea con una precisión mejorada. SkyWater, certificada según la norma de calidad ISO 13485 para dispositivos médicos, aprovechará su modelo de Tecnología como Servicio (TaaS) y sus capacidades de fabricación para respaldar este desarrollo.
Quantum-Si (QSI)와 SkyWater Technology는 QSI의 차세대 단백질 서열 분석 플랫폼인 Proteus™를 위한 소모품 개발을 위해 협력 관계를 확대하고 있습니다. 이는 2021년부터 이어온 1세대 Platinum® 플랫폼에 대한 기존 파트너십을 기반으로 합니다. SkyWater는 Platinum Pro에 대한 소모품 공급을 계속하는 동시에 Proteus 상용화를 지원할 것입니다. 새로운 플랫폼은 향상된 정확도로 동시에 대규모 단백질 서열 분석을 가능하게 하는 것을 목표로 합니다. 의료 기기를 위한 ISO 13485 품질 표준을 인증받은 SkyWater는 기술 서비스(TaaS) 모델과 제조 능력을 활용하여 이 개발을 지원할 것입니다.
Quantum-Si (QSI) et SkyWater Technology étendent leur collaboration pour développer les consommables pour Proteus™, la plateforme de séquençage de protéines de nouvelle génération de QSI. Cela s'appuie sur leur partenariat existant depuis 2021 concernant la première génération de la plateforme Platinum®. SkyWater continuera à fournir des consommables pour Platinum Pro tout en soutenant la commercialisation de Proteus. La nouvelle plateforme vise à permettre le séquençage simultané de grandes protéines avec une précision améliorée. SkyWater, certifiée selon la norme de qualité ISO 13485 pour les dispositifs médicaux, exploitera son modèle de Technologie en tant que Service (TaaS) et ses capacités de fabrication pour soutenir ce développement.
Quantum-Si (QSI) und SkyWater Technology erweitern ihre Zusammenarbeit zur Entwicklung der Verbrauchsmaterialien für Proteus™, QSI's nächste Generation der Proteinsequenzierungsplattform. Dies baut auf ihrer bestehenden Partnerschaft seit 2021 zur ersten Generation der Platinum®-Plattform auf. SkyWater wird weiterhin Verbrauchsmaterialien für Platinum Pro liefern und gleichzeitig die Kommerzialisierung von Proteus unterstützen. Die neue Plattform zielt darauf ab, eine gleichzeitige sequenzielle Analyse von großen Proteinmengen mit verbesserter Genauigkeit zu ermöglichen. SkyWater, zertifiziert nach dem Qualitätsstandard ISO 13485 für Medizinprodukte, wird sein Modell der Technologie als Dienstleistung (TaaS) und seine Fertigungskapazitäten nutzen, um diese Entwicklung zu unterstützen.
- Expansion of existing successful partnership with SkyWater Technology
- Development of next-generation Proteus platform with enhanced capabilities
- Continued supply agreement for Platinum Pro consumables
- Partner's ISO 13485 certification ensures medical device quality standards
- None.
Insights
The expanded collaboration between QSI and SkyWater represents a significant strategic development in semiconductor manufacturing for proteomics applications. The partnership's focus on developing consumables for the Proteus platform, following their successful work on the Platinum platform, demonstrates strong execution capability and manufacturing scalability. SkyWater's ISO 13485 certification and Technology as a Service model significantly de-risks the manufacturing process.
The transition to production support in Q2 2024 for the first-generation platform, coupled with the expansion into next-generation Proteus development, indicates a clear commercialization pathway. SkyWater's expertise in microfluidic biomedical devices and early-stage collaboration model could accelerate time-to-market while maintaining quality standards. This manufacturing partnership is important for QSI's competitive positioning in the emerging protein sequencing market.
The development of Proteus marks a significant technological advancement in proteomics research. The platform's promised capabilities for simultaneous large factor protein sequencing with high accuracy could potentially disrupt current proteomics workflows. The expansion from Platinum to Proteus demonstrates QSI's commitment to innovation and market leadership in Next-Generation Protein Sequencing.
The technology's potential applications in diagnostic biomarker discovery and treatment development could open new revenue streams and market opportunities. However, success will depend on the platform's ability to deliver on its promised performance metrics and gain adoption in research laboratories. The continued partnership with SkyWater suggests confidence in the technical feasibility of mass-producing these advanced consumables.
Sets stage for advanced scientific discovery of new diagnostic biomarkers and treatments for disease
Quantum-Si and SkyWater began partnering in 2021 on the first-generation Platinum® platform and announced transition to support production in the second quarter of 2024. SkyWater will continue to supply the consumables for the Platinum Pro product as the two companies expand their engagement to support commercialization of Proteus.
This cutting-edge solution is set to redefine proteomics with unprecedented output per sample, application flexibility and automation. By combining Quantum-Si’s expertise in biotechnology with SkyWater’s Technology as a Service (TaaS) manufacturing capabilities, the collaboration is poised to drive significant advancements in protein sequencing and to the field of proteomics.
"We’re pleased to build on past success together and move into this next product development program with momentum to drive the innovations for this revolutionary proteomics platform," said Ross Miller, SVP Commercial and A&D Business, SkyWater Technology. "This collaboration underscores SkyWater’s commitment to enabling transformative technologies that have the potential to reshape industries and improve lives."
"We are excited to expand our relationship with SkyWater around Platinum, and to apply the learnings and their unique capabilities to our next platform innovation," said Jeff Hawkins, President and CEO of Quantum-Si. "SkyWater’s manufacturing expertise and commitment to innovation make them an ideal partner as we work to commercialize this game-changing platform. With Platinum, we were the first to bring Next-Generation Protein Sequencing™ to researchers globally and we believe our new technology will enable us to further extend our leadership position in protein sequencing and allow us to extend our technology into other areas of proteomics.”
Leveraging its custom process development and robust manufacturing capabilities, SkyWater enables the unique technological needs of microfluidic biomedical devices from proof of concept to final qualification. Embracing a TaaS model, SkyWater facilitates early collaboration with system engineers and device designers, developing technology within a production environment. This approach expedites time-to-market, ensures quality from inception, and seamlessly scales to meet volume production demands.
SkyWater holds certification to the ISO 13485 Quality Standard for Medical Devices, affirming its ability to support the design, development, and fabrication of biomedical applications.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® instrument enables Next-Generation Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.
Forward Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway and its financial guidance for the full year 2024. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum® protein sequencing instrument and kits and the Company’s other products once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
About SkyWater Technology
SkyWater (NASDAQ: SKYT) is a
SkyWater Technology Forward-Looking Statements
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements that are based on the Company’s current expectations or forecasts of future events, rather than past events and outcomes, and such statements are not guarantees of future performance. Forward-looking statements are subject to risks, uncertainties and assumptions, which may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. Key factors that could cause the Company’s actual results to be different than expected or anticipated include, but are not limited to, factors discussed in the “Risk Factors” section of its annual report on Form 10-K and quarterly reports on Form 10-Q, and in other documents that the Company files with the SEC, which are available at http://www.sec.gov. The Company assumes no obligation to update any forward-looking statements, which speak only as of the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241120350902/en/
Quantum-Si Investor Contact
Doug Farrell, VP, Investor Relations
ir@quantum-si.com
Quantum-Si Media Contact
Katherine Atkinson, SVP, Commercial Marketing
media@quantum-si.com
SkyWater Company Contact:
Tara Luther, Director of Corporate Communications
tara.luther@skywatertechnology.com
SkyWater Media Contact:
Lauri Julian, Public Relations Strategist
lauri.julian@skywatertechnology.com
Source: Quantum-Si Incorporated
FAQ
What is the purpose of Quantum-Si's (QSI) collaboration with SkyWater Technology?
When did Quantum-Si (QSI) and SkyWater Technology begin their initial partnership?
What are the key features of Quantum-Si's (QSI) new Proteus platform?
When will SkyWater Technology transition to support production for Quantum-Si's (QSI) Platinum platform?
